Analyst Research Report Snapshot

Title:

MORPHOSYS - ADVANCING ON ALL FRONTS

Price:

$10.00

Provider:

Edison Investment Research

Date:

07 Jan 2014

Pages:

8

Type:

AcrobatPDF

Companies referenced:

MORG.DE

Available for Immediate Download
Summary:

Both MorphoSys's proprietary and non-proprietary pipelines are advancing well. Data from the trials with its three proprietary clinical products are expected in FY14, as well as new trials with those partnered with GSK and Celgene. It now has two Phase III and eight Phase II in its non-proprietary pipeline, including bimagrumab, which has breakthrough designation from the FDA. MorphoSys is likely to strengthen its portfolio further in 2014 by in-licensing programmes. We increase our valuation to €1.60bn.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.